Britain and America have concluded a major trade agreement that will guarantee no import taxes on UK pharmaceutical shipments going into the US market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase spending on drugs through the National Health Service (NHS). This commitment guarantees that import taxes on these crucial goods will stay at nothing for a duration of the next three years.
This deal is in response to recent threats to hike duties on branded drug products, with increases floated as high as 100%.
"This deal between the UK reinforces the worldwide climate for innovative medicines and establishes much-needed balance to transatlantic medicine commerce," a statement said.
Commercial Impact
Drugs constitute one of the Britain's largest exports to the United States, which is clearly the primary market for large UK drugmakers.
Trade data reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that period.
"This agreement protects jobs, boosts funding and facilitates the UK to emerge as a international leader for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement entails several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount pharmaceutical firms must refund to the NHS to control costs will be restricted at 15%. Previously, rebates topped 20%.
Broader Context
The pact comes amid a ongoing dispute between the sector and the ministers over drug pricing and regulatory access.
These tensions were intensified by claims that US customers were paying a premium for the identical medicines than people in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official stated that the NHS had to spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its resources over the last ten years.
